Congenital growth hormone deficiency (GHD) is a rare disease caused by disorders affecting the morphogenesis and function of the pituitary gland. It is sometimes found in isolation but is more frequently associated with multiple pituitary hormone deficiency. In some cases, GHD may have a genetic basis. The many clinical signs and symptoms include hypoglycaemia, neonatal cholestasis and micropenis. Diagnosis should be made by laboratory analyses of the growth hormone and other pituitary hormones, rather than by cranial imaging with magnetic resonance imaging. When diagnosis is confirmed, hormone replacement should be initiated. Early GH replacement therapy leads to more positive outcomes, including reduced hypoglycaemia, growth recovery, metabolic asset, and neurodevelopmental improvements.

Management of Neonatal Isolated and Combined Growth Hormone Deficiency: Current Status / Stagi, Stefano; Tufano, Maria; Chiti, Nicolò; Cerutti, Matteo; Li Pomi, Alessandra; Aversa, Tommaso; Wasniewska, Malgorzata. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1422-0067. - ELETTRONICO. - 24:(2023), pp. 10114.0-10114.0. [10.3390/ijms241210114]

Management of Neonatal Isolated and Combined Growth Hormone Deficiency: Current Status

Stagi, Stefano;Tufano, Maria;Cerutti, Matteo;
2023

Abstract

Congenital growth hormone deficiency (GHD) is a rare disease caused by disorders affecting the morphogenesis and function of the pituitary gland. It is sometimes found in isolation but is more frequently associated with multiple pituitary hormone deficiency. In some cases, GHD may have a genetic basis. The many clinical signs and symptoms include hypoglycaemia, neonatal cholestasis and micropenis. Diagnosis should be made by laboratory analyses of the growth hormone and other pituitary hormones, rather than by cranial imaging with magnetic resonance imaging. When diagnosis is confirmed, hormone replacement should be initiated. Early GH replacement therapy leads to more positive outcomes, including reduced hypoglycaemia, growth recovery, metabolic asset, and neurodevelopmental improvements.
2023
24
0
0
Goal 3: Good health and well-being
Stagi, Stefano; Tufano, Maria; Chiti, Nicolò; Cerutti, Matteo; Li Pomi, Alessandra; Aversa, Tommaso; Wasniewska, Malgorzata
File in questo prodotto:
File Dimensione Formato  
ijms-24-10114.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 352.13 kB
Formato Adobe PDF
352.13 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1413044
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 7
social impact